Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2014 (2014), Article ID 310329, 7 pages
http://dx.doi.org/10.1155/2014/310329
Review Article

Emerging Therapies for Noninfectious Uveitis: What May Be Coming to the Clinics

Ocular Imaging Research and Reading Center, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, 3902 Leavenworth Street, 985540 Nebraska Medical Center, Omaha, NE 68198-5540, USA

Received 16 January 2014; Revised 25 March 2014; Accepted 25 March 2014; Published 24 April 2014

Academic Editor: Manfred Ziehrut

Copyright © 2014 Jose R. Maya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Fel, E. Aslangul, and C. Le Jeunne, “Eye and corticosteroid's use,” Presse Medicale, vol. 41, no. 4, pp. 414–421, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Kruh and C. S. Foster, “Corticosteroid-sparing agents: conventional systemic immunosuppressants,” Developments in Ophthalmology, vol. 51, pp. 29–46, 2012. View at Google Scholar
  3. M. E. Truchetet, M. D. Mossalayi, and K. Boniface, “IL-17 in the rheumatologist's line of sight,” BioMed Research International, vol. 2013, Article ID 295132, 18 pages, 2013. View at Publisher · View at Google Scholar
  4. W. Chi, P. Yang, B. Li et al., “IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease,” Journal of Allergy and Clinical Immunology, vol. 119, no. 5, pp. 1218–1224, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. W. Chi, X. Zhu, P. Yang et al., “Upregulated IL-23 and IL-17 in Behcet patients with active uveitis,” Investigative Ophthalmology & Visual Science, vol. 49, no. 7, pp. 3058–3064, 2008. View at Google Scholar
  6. W. Hueber, D. D. Patel, T. Dryja et al., “Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis,” Science Translational Medicine, vol. 2, no. 52, Article ID 52ra72, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. S. N. Sehgal, “Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression,” Clinical Biochemistry, vol. 31, no. 5, pp. 335–340, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. A. E. Cohen, C. Assang, M. A. Patane, S. From, and M. Korenfeld, “Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating noninfectious anterior uveitis,” Ophthalmology, vol. 119, no. 1, pp. 66–73, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Issafras, J. A. Corbin, I. D. Goldfine, and M. K. Roell, “Detailed mechanistic analysis of gevokizumab, an allosteric anti-il-1beta antibody with differential receptor-modulating properties,” Journal of Pharmacology and Experimental Therapeutics, vol. 348, no. 1, pp. 202–215, 2014. View at Google Scholar
  10. F. Iannone and G. Lapadula, “The inhibitor of costimulation of T cells: abatacept,” Journal of Rheumatology Supplement, vol. 89, pp. 100–102, 2012. View at Google Scholar
  11. I. Navarro-Millán, J. A. Singh, and J. R. Curtis, “Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor,” Clinical Therapeutics, vol. 34, no. 4, pp. 788.e3–802.e3, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Reichert, “Which are the antibodies to watch in 2012?” mAbs, vol. 4, no. 1, pp. 1–3, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. D. Dick, I. Tugal-Tutkun, S. Foster et al., “Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials,” Ophthalmology, vol. 120, no. 4, pp. 777–787, 2013. View at Google Scholar
  14. R. B. Nussenblatt, G. Byrnes, H. N. Sen et al., “A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization,” Retina, vol. 30, no. 10, pp. 1579–1587, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Krishnadev, F. Forooghian, C. Cukras et al., “Subconjunctival sirolimus in the treatment of diabetic macular edema,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 249, no. 11, pp. 1627–1633, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. V. A. Shanmuganathan, E. M. Casely, D. Raj et al., “The efficacy of sirolimus in the treatment of patients with refractory uveitis,” British Journal of Ophthalmology, vol. 89, no. 6, pp. 666–669, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. B. N. Phillips and K. J. Wroblewski, “A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis,” Journal of Ophthalmic Inflammation and Infection, vol. 1, no. 1, pp. 29–34, 2011. View at Google Scholar
  18. Q. D. Nguyen, M. A. Ibrahim, A. Watters et al., “Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study,” Journal of Ophthalmic Inflammation and Infection, vol. 3, no. 1, article 32, 2013. View at Google Scholar
  19. C. Cavelti-Weder, A. Babians-Brunner, C. Keller et al., “Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes,” Diabetes Care, vol. 35, no. 8, pp. 1654–1662, 2012. View at Google Scholar
  20. A. Gül, I. Tugal-Tutkun, C. A. Dinarello et al., “Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study,” Annals of the Rheumatic Diseases, vol. 71, no. 4, pp. 563–566, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Y. Lai, “What’s new in uveitis and ocular inflammation?” Asia-Pacific Journal of Ophthalmology, vol. 2, no. 4, 2013. View at Google Scholar
  22. Gevokizumab for Active Scleritis, NCT01835132, http://www.clinicaltrials.gov.
  23. E. Furrer, M. Berdugo, C. Stella et al., “Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-α single-chain antibody, upon topical administration to the rabbit eye,” Investigative Ophthalmology and Visual Science, vol. 50, no. 2, pp. 771–778, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Ottiger, M. A. Thiel, U. Feige, P. Lichtlen, and D. M. Urech, “Efficient intraocular penetration of topical anti-TNF-α single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer,” Investigative Ophthalmology and Visual Science, vol. 50, no. 2, pp. 779–786, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. M. A. Thiel, A. Wild, M. K. Schmid et al., “Penetration of a topically administered anti-tumor necrosis factor alpha antibody fragment into the anterior chamber of the human eye,” Ophthalmology, vol. 120, no. 7, pp. 1403–1408, 2013. View at Google Scholar
  26. Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis, NCT00823173, http://www.clinicaltrials.gov.
  27. G. S. Hazlewood, C. Barnabe, S. G. Barr, and L. Martin, “Abatacept use after failure of multiple biologic agents in patients with severe rheumatoid arthritis,” Journal of Clinical Rheumatology, vol. 18, no. 8, pp. 416–418, 2012. View at Google Scholar
  28. F. Zulian, M. Balzarin, F. Falcini et al., “Abatacept for severe anti-tumor necrosis factor α refractory juvenile idiopathic arthritis-related uveitis,” Arthritis Care and Research, vol. 62, no. 6, pp. 821–825, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. Abatacept in the Treatment of Uveitis, NCT1279954, http://www.clinicaltrials.gov.
  30. J. Horwath-Winter, O. Schmut, E.-M. Haller-Schober, A. Gruber, and G. Rieger, “Iodide iontophoresis as a treatment for dry eye syndrome,” British Journal of Ophthalmology, vol. 89, no. 1, pp. 40–44, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. “Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study,” NCT01059955, http://www.clinicaltrials.gov.
  32. C. Schultz, “Voclosporin as a Treatment for Noninfectious Uveitis,” Ophthalmology and Eye Diseases, vol. 5, pp. 5–10, 2013. View at Google Scholar
  33. Y. J. Sepah, E. H. Michelle, B. Metcalf et al., “Voclosporin: a potentially promising therapeutic agent for noninfectious uveitis,” Expert Review of Ophthalmology, vol. 6, no. 3, pp. 281–286, 2011. View at Publisher · View at Google Scholar · View at Scopus